Citius Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense
Citius Pharmaceuticals, Inc. (CTXR) reported Share-based Payment Arrangement, Expense of $1.67 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-05-15
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.67M, a 38.26% decline year-over-year.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.64M, a 0.00% change year-over-year.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $3.06M, a 160.77% increase year-over-year.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $2.70M, a 12.23% decline year-over-year.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2025 was $10.84M, a 0.00% change from fiscal 2024.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2024 was $10.84M, a 63.77% increase from fiscal 2023.
- Citius Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2023 was $6.62M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $1.67M 10-Q · filed 2026-05-15 | $3.37M 10-Q · filed 2026-05-15 | |||
| 2025-09-30 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $4.70M derived: sum of 2 quarters · filed 2025-12-23 | $7.40M derived: sum of 3 quarters · filed 2025-12-23 | $10.84M 10-K · filed 2025-12-23 | |
| 2025-06-30 | $3.06M 10-Q · filed 2025-08-12 | $5.76M derived: sum of 2 quarters · filed 2025-08-12 | $9.20M 10-Q · filed 2025-08-12 | $9.93M derived: sum of 4 quarters · filed 2025-12-23 | |
| 2025-03-31 | $2.70M 10-Q · filed 2025-05-14 | $5.23M 10-Q · filed 2025-05-14 | $6.86M derived: sum of 3 quarters · filed 2025-12-23 | $8.04M derived: sum of 4 quarters · filed 2025-12-23 | |
| 2024-12-31 | $2.52M 10-Q · filed 2025-02-14 | $4.16M derived: sum of 2 quarters · filed 2025-12-23 | $5.34M derived: sum of 3 quarters · filed 2025-12-23 | $8.42M derived: sum of 4 quarters · filed 2025-12-23 | |
| 2024-09-30 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $2.81M derived: sum of 2 quarters · filed 2025-12-23 | $5.89M derived: sum of 3 quarters · filed 2025-12-23 | $10.84M 10-K · filed 2025-12-23 | $11.84M 10-K · filed 2024-12-27 |
| 2024-06-30 | $1.17M 10-Q · filed 2024-08-12 | $4.25M derived: sum of 2 quarters · filed 2025-05-14 | $9.20M 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | $3.08M 10-Q · filed 2025-05-14 | $6.14M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $3.06M 10-Q · filed 2025-02-14 | ||||
| 2023-09-30 | $6.62M 10-K · filed 2024-12-27 | ||||
| 2023-03-31 | $1.17M 10-Q · filed 2024-05-14 | $2.37M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $1.20M 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |